摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4’-氨基-2’-羟基苯乙酮 | 2476-29-1

中文名称
4’-氨基-2’-羟基苯乙酮
中文别名
1-(4-氨基-2-羟基苯基)乙酮;4`-氨基-2`-羟基苯乙酮;1-(4-氨基-2-羟基苯基)-1-乙酮;4'-氨基-2'-羟基苯乙酮;4-氨基-2-羟基苯乙酮
英文名称
4-amino-2-hydroxy-acetophenone
英文别名
1-(4-amino-2-hydroxyphenyl)ethan-1-one;1-(4-amino-2-hydroxyphenyl)ethanone;4'-amino-2'-hydroxyacetophenone;4-amino-2-hydroxyacetophenone;4-acetyl-3-hydroxyaniline;1-(4-amino-2-hydroxy-phenyl)-ethanone
4’-氨基-2’-羟基苯乙酮化学式
CAS
2476-29-1
化学式
C8H9NO2
mdl
MFCD00100636
分子量
151.165
InChiKey
QQZFVONVJPXCSQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    129-131
  • 沸点:
    331.7±22.0 °C(Predicted)
  • 密度:
    1.242±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    63.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xn
  • 危险类别码:
    R22,R36/37/38
  • 海关编码:
    2922509090
  • 安全说明:
    S22,S26,S36/37/39
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温、密封保存,并保持干燥。

SDS

SDS:0e797e37cda4da15fca94bdc2f028b98
查看
Name: 1-(4-Amino-2-hydroxyphenyl)ethan-1-one Material Safety Data Sheet
Synonym: None know
CAS: 2476-29-1
Section 1 - Chemical Product MSDS Name:1-(4-Amino-2-hydroxyphenyl)ethan-1-one Material Safety Data Sheet
Synonym:None know

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
2476-29-1 1-(4-Amino-2-hydroxyphenyl)ethan-1-one 80+% unlisted
Hazard Symbols: XN
Risk Phrases: 22 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2476-29-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 129 - 131 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9NO2
Molecular Weight: 151.17

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2476-29-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Amino-2-hydroxyphenyl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 2476-29-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2476-29-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2476-29-1 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    4’-氨基-2’-羟基苯乙酮 在 palladium on activated charcoal lithium hydroxide 、 3 A molecular sieve 、 氢气potassium carbonate 作用下, 以 四氢呋喃甲醇丙酮 为溶剂, 生成 4-[(4-acetyl-N-benzyl-3-hydroxyanilino)methyl]-3-methoxybenzoic acid
    参考文献:
    名称:
    Brown, Frederick J.; Bernstein, Peter R.; Cronk, Laura A., Journal of Medicinal Chemistry, 1989, vol. 32, # 4, p. 811 - 826
    摘要:
    DOI:
  • 作为产物:
    描述:
    二乙酰基-3-氨基苯酚盐酸 、 aluminum (III) chloride 作用下, 以 为溶剂, 生成 4’-氨基-2’-羟基苯乙酮
    参考文献:
    名称:
    使用 Fe25Ru75@SILP 催化剂对苯乙酮衍生物进行选择性加氢脱氧:一种合成烷基酚和苯胺的实用方法
    摘要:
    基于广泛的羟基-、氨基-和硝基-苯乙酮衍生物作为容易获得的底物的选择性加氢脱氧,开发了一种生产有价值的烷基酚和苯胺的通用合成途径。固定在咪唑基负载型离子液相 (Fe 25 Ru 75 @SILP) 上的双金属铁钌纳米粒子可作为高活性和选择性催化剂,用于侧链脱氧而不会使芳环氢化。该催化系统允许在连续流动条件下运行,具有高稳定性和灵活性,如 3',5'-二甲氧基-4'-羟基苯乙酮和 4'-羟基壬苯酮作为模型底物的交替转化所证明的那样。
    DOI:
    10.1039/d1gc04189d
点击查看最新优质反应信息

文献信息

  • [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    申请人:COFERON INC
    公开号:WO2015106292A1
    公开(公告)日:2015-07-16
    Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.
    本文描述了一种单体,当与性介质中的另一个、两个、三个或更多其他单体接触时,能够形成生物学上有用的多聚体。在一个方面,这种单体可能能够在性介质(例如体内)中与另一个单体结合以形成多聚体(例如二聚体)。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在性介质中,这些考虑到的单体可以通过每个连接元素结合在一起,因此可以同时调节一个或多个生物分子,例如,调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
  • A novel entry to xanthones by an intramolecular Diels-Alder reaction involving 2-(1,2-dichlorovinyloxy) aryl dienones
    作者:Katerina Otrubova、Anne E. Fitzgerald、Neelakandha S. Mani
    DOI:10.1016/j.tet.2018.08.007
    日期:2018.9
    of synthetic methods are described in the literature for the preparation of xanthones—a prominent class of tricyclic molecules that occur widely in nature. Majority of these reported methods involve linking the two aromatic rings and forming the central pyrone ring using a variety of classical and non-classical cyclization strategies. In a conceptually different approach, we describe here a new xanthone
    文献中描述了多种用于制备氧杂蒽酮的合成方法,所述杂合酮是自然界中广泛存在的一类重要的三环分子。这些报道的方法大多数涉及使用各种经典和非经典环化策略连接两个芳环并形成中心喃环。在概念上不同的方法中,我们在这里描述了一种新的x吨酮合成方法,其中吡喃酮和第二芳环均通过涉及2-(1,2-二氯乙烯基氧基)芳基二烯酮的分子内环加成反应在一个步骤中锻造而成。
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
    申请人:Kandula Mahesh
    公开号:US20150133407A1
    公开(公告)日:2015-05-14
    The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.
    本发明涉及公式I的化合物或其药用可接受的盐,以及它们的聚合物、溶剂化物、对映体、立体异构体和合物。包含有效量的公式I化合物的药物组合物,以及用于治疗呼吸系统疾病的方法,可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病(COPD)、呼吸肌疾病和急性喉咙痛的疼痛。
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS
    申请人:Kandula Mahesh
    公开号:US20150307446A1
    公开(公告)日:2015-10-29
    The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.
    该发明涉及公式I的化合物或其药用可接受盐,以及其多晶型、溶剂合物、对映体、立体异构体和合物。包括有效量的公式I化合物的药物组合物,以及用于治疗粘膜炎的方法可以制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗与消化道内膜疼痛性炎症和溃疡相关的黏膜疾病。
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOCAL PAIN
    申请人:Kandula Mahesh
    公开号:US20150119423A1
    公开(公告)日:2015-04-30
    The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains.
    本发明涉及公式I的化合物或其药用可接受的盐,以及它们的多种晶型、溶剂化物、对映异构体、立体异构体和合物。包括有效量的公式I化合物的药物组合物,以及用于治疗局部疼痛的方法,可以口服、颊部、直肠、局部、经皮、经粘膜、静脉内、非肠道给药、糖浆或注射等方式进行配方。此类组合物可用于治疗中等到重度疼痛、神经性疼痛、带状疱疹后遗神经痛和风湿性疼痛。
查看更多